Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
NCT05837624
· ctgov
recruiting
phase phase-4
- Enrollment
- 21
- Start
- 2024-12-03
- Completion
- 2027-08-01
- Last updated
- 2026-11-03
- Has results
- False
- Countries
- Canada
Conditions
Tagged with
Interventions
-
Estetrol/Drospirenone
DRUG
6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
Eligibility criteria
Inclusion Criteria:
* Equal to or greater than 18 years old
* Has at least one ovarian endometrioma, of at least 3 cm
* Seeking a hormonal treatment for their endometrioma(s)
Exclusion criteria:
* Any allergy or contraindication to the study drug
* Inability to provide informed consent
* Any hormone use, from the following list, within last 3 months (excluding hormones used for ovarian stimulation for fertility treatments): Estrogen (agonist or antagonist), Progestogen (agonist or antagonist), Androgen (agonist or antagonist), GnRH (agonist or antagonist), Cabergoline
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine